Westend, Director of Cava Group CAVA, has filed 14 purchases and 8 sales on the open market. Over the past 12 months that comes to a net sale of $268.9M. The latest trade was on 06/15.

Westend

Director

Company: Cava Group CAVA
First filing: 23/01/11

Trades: 45 trades
Buys / sales: 14 / 8
12-month net buying: −$268.9M
Last trade: 06/15

Trading activity

Transactions

	Trade type
Cava GroupCAVA	Open-market sale	06/15	06/17	3,000,000 sh	$90.30	$270,900,000	−31.6%
Lexicon PharmaceuticalsLXRX	Open-market buy	02/02	02/04	1,538,462 sh	$1.30	$2,000,000.6	No record
Cava GroupCAVA	Open-market sale	24/11/18	24/11/20	8,000,000 sh	$134.13	$1,073,040,000	−45.7%
Cava GroupCAVA	Open-market sale	24/08/26	24/08/28	6,000,000 sh	$116.36	$698,160,000	−25.5%
Cava GroupCAVA	Open-market sale	24/06/05	24/06/07	3,000,000 sh	$87.25	$261,750,000	−11.3%
Cava GroupCAVA	Open-market sale	24/03/21	24/03/25	2,000,000 sh	$66.25	$132,500,000	−7.0%
Cava GroupCAVA	Open-market sale	24/02/27	24/02/29	3,500,000 sh	$53.60	$187,600,000	−10.9%
SRRK	Open-market buy	23/10/12	23/10/16	2,199,931 sh2 trades	$6.86avg.	$15,086,782.35	+24.3%
Lexicon PharmaceuticalsLXRX	Open-market buy	23/06/05	23/06/05	27,775,050 sh	$2.60	$72,215,130	+54.6%
WW InternationalWW	Open-market sale	23/05/10	23/05/11	14,818,300 sh	$7.15	$105,950,845	−100.0%
Scholar Rock HoldingSRRK	Open-market buy	23/04/28	23/05/02	31,557 sh	$6.43	$202,911.51	+0.3%
Crescent BiopharmaCBIO	Open-market buy	23/02/24	23/02/28	100,000 sh	$1.70	$170,000	+1.2%
CBIO	Open-market buy	23/02/21–23/02/23	23/02/23	400,000 sh3 trades	$1.78avg.	$711,000	+4.9%
CBIO	Open-market buy	23/02/15–23/02/17	23/02/17	1,515,266 sh3 trades	$2.00avg.	$3,031,646.88	+23.1%
Crescent BiopharmaCBIO	Open-market buy	23/02/09	23/02/13	11,451 sh	$3.24	$37,101.24	+0.2%
Scholar Rock HoldingSRRK	Open-market sale	23/01/09	23/01/11	1,094 sh	$9.48	$10,371.12	−0.0%
Scholar Rock HoldingSRRK	Open-market buy	23/01/05	23/01/09	48,774 sh	$9.33	$455,061.42	+0.5%